The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma ... after other treatments failed. But the asthma indication could add as much as $4 billion, according to the most ...

Sanofi and partner Regeneron have picked up an approval in Europe for Dupixent in asthma, unlocking an important new indication for ... 2 inflammation occurs in allergic-type diseases, and in ...

Dupixent is a brand-name injection that doctors prescribe to treat certain conditions, including atopic dermatitis and asthma ... drug interactions, allergic reactions, or adverse effects.

Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma ... or other allergic processes in ...

If that doesn't work, your doctor may give you a shot of a medicine called dupilumab (Dupixent ... if you live in a dry climate. Treat allergies and asthma. Continue using a corticosteroid ...

It was originally approved in 2003 for the treatment of moderate to severe asthma ... For its new indication, Xolair’s safety and efficacy in reducing allergic reactions in patients with ...

Fisher, PhD, of the University of North Carolina at Chapel Hill, and colleagues in the Annals of Allergy, Asthma & Immunology ...

2024 brought some major advancements in medicine. That includes the approval of "innovative" drugs like Tryvio for high blood pressure, Neffy for severe allergic reactions and Dupixent for chronic ...

Safety results in all LIBERTY-CUPID phase 3 studies were generally consistent with the known safety profile of Dupixent in its approved indications. Adverse events more commonly observed with Dupixent ...

Safety results in all LIBERTY-CUPID Phase 3 trials were generally consistent with the known safety profile of Dupixent in its approved indications. Adverse events more commonly observed with Dupixent ...